Seasonality and changes in ADHD medication sales to pharmacies in Poland from 2018 to 2023
Prospects in Pharmaceutical Sciences · 30.06.2026 · 24 (2) · 161-168
DOI: 10.56782/pps.905 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prospects in Pharmaceutical Sciences, online erschienen am 30.06.2026. Verfasst von Marcin Rzeszutek und 1 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
To investigate the seasonality and the impact of the COVID-19 pandemic on ADHD medication, including immediate-release (IR), long-acting (LA), and osmotic-controlled release oral delivery system (OROS) methylphenidate and atomoxetine consumption in Poland between February 2018 and April 2024. Data on ADHD medication consumption were analyzed using defined daily doses (DDD) per 1,000 inhabitants per day. Seasonal variation was assessed with the Holt-Winters method, and changes post-March 2020 were evaluated by comparing pre- and post-pandemic monthly values. The test statistic, denoted as Q, measured pairs of months where post-pandemic values exceeded pre-pandemic ones, with a p-value < 0.05 indicating a significant increase. There was a clear seasonal pattern in ADHD medication consumption, with a decrease observed in June, July, and August for all the drugs and formulations studied. A statistically significant increase in consumption (p < 0.05) was observed for ADHD medications overall, as well as for atomoxetine and the IR and LA formulations of methylphenidate. However, no significant increase was noted for the OROS formulation of methylphenidate after the onset of the pandemic in March 2020. The consumption of ADHD medications in Poland has shown a notable increase in recent years. The identified seasonality patterns and the observed rise in consumption may provide valuable insights for improving healthcare system planning and optimization, as well as for preparing to address emerging challenges.
Zitieren
APA
Rzeszutek, M., & Wolańczyk, T. (2026). Seasonality and changes in ADHD medication sales to pharmacies in Poland from 2018 to 2023. Prospects in Pharmaceutical Sciences, 24(2), 161-168. https://doi.org/10.56782/pps.905
Vancouver
Rzeszutek M, Wolańczyk T. Seasonality and changes in ADHD medication sales to pharmacies in Poland from 2018 to 2023. Prospects in Pharmaceutical Sciences. 2026;24(2):161-168. doi:10.56782/pps.905
BibTeX
@article{Rzeszutek2026,
author = {Rzeszutek, Marcin and Wolańczyk, Tomasz},
title = {Seasonality and changes in ADHD medication sales to pharmacies in Poland from 2018 to 2023},
journal = {Prospects in Pharmaceutical Sciences},
year = {2026},
volume = {24},
number = {2},
pages = {161--168},
doi = {10.56782/pps.905}
}
EUVIMED